

Study protocol

Open Access

## Protocol for the immediate delivery versus expectant care of women with preterm prelabour rupture of the membranes close to term (PPROM) Trial [ISRCTN44485060]

Jonathan M Morris<sup>1</sup>, Christine L Roberts\*<sup>2</sup>, Caroline A Crowther<sup>3</sup>, Sarah L Buchanan<sup>1</sup>, David J Henderson-Smart<sup>2</sup> and Glenn Salkeld<sup>4</sup>

Address: <sup>1</sup>Department of Obstetrics and Gynaecology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia, <sup>2</sup>Centre for Perinatal Health Services Research, PO Box M40, Missenden Rd NSW 2050, Australia, <sup>3</sup>Department of Obstetrics and Gynaecology, The University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide 5006, Australia and <sup>4</sup>School of Public Health, Edward Ford Building, University of Sydney NSW 2006, Australia

Email: Jonathan M Morris - [jmorris@med.usyd.edu.au](mailto:jmorris@med.usyd.edu.au); Christine L Roberts\* - [croberts@perinatal.usyd.edu.au](mailto:croberts@perinatal.usyd.edu.au); Caroline A Crowther - [caroline.crowther@adelaide.edu.au](mailto:caroline.crowther@adelaide.edu.au); Sarah L Buchanan - [sarahlbuchanan@hotmail.com](mailto:sarahlbuchanan@hotmail.com); David J Henderson-Smart - [dhs@perinatal.usyd.edu.au](mailto:dhs@perinatal.usyd.edu.au); Glenn Salkeld - [glenns@health.usyd.edu.au](mailto:glenns@health.usyd.edu.au)

\* Corresponding author

Published: 23 March 2006

Received: 23 November 2005

*BMC Pregnancy and Childbirth* 2006, **6**:9 doi:10.1186/1471-2393-6-9

Accepted: 23 March 2006

This article is available from: <http://www.biomedcentral.com/1471-2393/6/9>

© 2006 Morris et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Preterm prelabour rupture of membranes (PPROM) complicates up to 2% of all pregnancies and is the cause of 40% of all preterm births. The optimal management of women with PPRM prior to 37 weeks, is not known. Furthermore, diversity in current clinical practice suggests uncertainty about the appropriate clinical management.

There are two options for managing PPRM, expectant management (a wait and see approach) or early planned birth. Infection is the main risk for women in which management is expectant. This risk need to be balanced against the risk of iatrogenic prematurity if early delivery is planned. The different treatment options may also have different health care costs. Expectant management results in prolonged antenatal hospitalisation while planned early delivery may necessitate intensive care of the neonate for problems associated with prematurity.

**Methods/Design:** We aim to evaluate the effectiveness of early planned birth compared with expectant management for women with PPRM between 34 weeks and 36<sup>6</sup> weeks gestation, in a randomised controlled trial. A secondary aim is a cost analysis to establish the economic impact of the two treatment options and establish the treatment preferences of women with PPRM close to term.

The early planned birth group will be delivered within 24 hours according to local management protocols. In the expectant management group birth will occur after spontaneous labour, at term or when the attending clinician feels that birth is indicated according to usual care. Approximately 1812 women with PPRM at 34–36<sup>6</sup> weeks gestation will be recruited for the trial.

The primary outcome of the study is neonatal sepsis. Secondary infant outcomes include respiratory distress, perinatal mortality, neonatal intensive care unit admission, assisted ventilation and early infant development. Secondary maternal outcomes include chorioamnionitis, postpartum infection treated with antibiotics, antepartum haemorrhage, induction of labour, mode of delivery, maternal satisfaction with care, duration of hospitalisation, and maternal wellbeing at four months postpartum.

**Discussion:** This trial will provide evidence on the optimal care for women with PPRM close to term (34–37 weeks gestation). Consideration of both the clinical and economic sequelae of the management of PPRM will enable informed decision making and guideline development.

**Background**

Prelabour rupture of the membranes (rupture of the membranes prior to the onset of labour) occurs in 20% of all births and 40% of all preterm births [1-3]. When prelabour rupture of the membranes occurs **at term** there is good evidence that early delivery is associated with a lower incidence of maternal infection and increased maternal satisfaction compared with expectant management [2]. However, the optimal management of women with **preterm** prelabour rupture of membranes (PPROM) prior to 37 weeks, is not known.

**PPROM near term: a management dilemma**

Following membrane rupture the preterm fetus is at risk of a number of complications such as: prematurity, placental abruption, ascending infection, intrapartum fetal distress and cord prolapse [4-6]. Abruptio placentae complicates pregnancy for 5-6% of women with PPRM [5]. As histological chorioamnionitis is more common in women with pregnancies complicated with PPRM compared with preterm or term controls [7], infection is the main risk for women in which management is expectant. These risks need to be balanced against the attendant risk of iatrogenic prematurity if early delivery is planned.

At extreme preterm gestations (less than 30 weeks), in the absence of maternal or fetal compromise, there is unanimity in that expectant management to allow further fetal maturation is desirable [8]. This is because the preterm fetus born prior to 30 weeks has increased risk of neonatal mortality, intraventricular haemorrhage, hyaline membrane disease and necrotizing enterocolitis. These risks, associated with immaturity, are reduced as the gestational age extends beyond 30 weeks [9].

At gestations nearer to term the benefit to the fetus of pregnancy prolongation following PPRM is uncertain such that by 34 weeks it has been suggested that there is no longer benefit for the fetus in the face of risks of intra-uterine infection [10]. Decisions to electively deliver a fetus preterm however require grounding in good clinical evidence as mild prematurity is associated with a significant health burden [11]. On the other hand, expectant management means mothers are often hospitalised for

prolonged periods with the consequent health budgetary implications.

**Fetal and neonatal risks at 34-37 weeks gestation**

Clinical decision-making requires consideration of the potential risks and benefits of induction of labour against expectant management with delivery at term or when complications such as chorioamnionitis intervene necessitating delivery. The aim of such management is to maximise the benefits of fetal maturity while avoiding the potential harms of remaining in utero. At gestations between 34 and 37 weeks, whilst the neonate is potentially at increased risk of respiratory distress, difficulty with thermoregulation and difficulty with breast feeding these risks need to be balanced against the increased incidence of chorioamnionitis associated with expectant management in women with PPRM [2]. Histological evidence of chorioamnionitis is present in up to 50% of women who give birth preterm and is often not associated with clinical symptoms or signs [12]. Chorioamnionitis is a known significant risk factor for the neonate for the development of cerebral palsy [12,13]. It is possible that there are increased risks of long term adverse neurological outcomes in those infants whose mothers are managed expectantly with PPRM by increasing their duration of exposure to often subclinical chorioamnionitis.

**Systematic review of the evidence on care of PPRM <37 weeks**

We have published a protocol for a Cochrane systematic review of randomised controlled trials to assess immediate delivery compared with expectant care in women with ruptured membranes between 34 and 37 weeks [14]. Our MEDLINE search used the terms (premature or preterm) and (rupture of membranes) or 'PROM' and (induction of labour) and randomised controlled trial) and identified three randomised controlled trials (outlined below) that we have included in a meta-analysis (Table 1).

Spinnato studied 47 patients with PPRM who had documented fetal lung maturation and randomised them to immediate or delayed delivery [15]. Expectant management was associated with increased maternal sepsis but the study lacked power to detect any significant neonatal

**Table 1: Meta-analysis of three trials comparing early planned delivery versus expectant management for preterm premature ruptured membranes between 34-37 weeks.**

Outcome	No. of Trials	No. of Women	Immediate Delivery	Expectant Care	RR (95% CI)
Caesarean Section	2	140	8/72 (11.1%)	6/68 (8.8%)	1.21 (0.45 - 3.28)
Chorioamnionitis	3	260	8/129 (6.2%)	31/131 (23.6%)	0.25 (0.12 - 0.53)
Neonatal Sepsis	3	257	9/128 (7.0%)	8/129 (6.2%)	1.00 (0.41 - 2.45)
RDS	3	257	5/128 (3.9%)	3/129 (2.3%)	1.56 (0.41 - 5.97)
Perinatal Mortality	3	260	2/129 (1.6%)	2/131 (1.5%)	1.24 (0.19 - 8.06)

morbidity. In contrast, Mercer et al (n = 93) found a non-significant 52% increase in maternal infectious morbidity with expectant management but a similar incidence of abdominal delivery and neonatal infection [16]. Both Spinnato and Mercer required amniocentesis and biochemical suggestion of pulmonary maturity prior to being eligible in the study [15,16].

Naef et al randomised 120 women to expectant management or immediate delivery and found no clinically significant neonatal advantages to expectant management of ruptured membranes at this gestational age [17]. Additionally there was a decrease in antepartum hospitalization in those women randomized to immediate delivery. The sample size was insufficient to detect changes in sepsis or potentially clinically significant differences in respiratory distress.

Overall, there was insufficient power to detect differences in important endpoints such as neonatal sepsis, respiratory distress, newborn intensive care resource use or economic outcomes (Table 1). Although no differences in neonatal sepsis were seen, the systematic review suggests that over 1 in 20 babies exposed to PPRM at 34–37 weeks are at risk of neonatal sepsis (Table 1). Although immediate delivery was associated with a significant decrease in chorioamnionitis compared with those pregnancies that were managed expectantly, chorioamnionitis is an intermediate histological outcome and does not necessarily reflect maternal or infant morbidity. Thus there is insufficient evidence on the benefits and harms of immediate delivery compared with expectant care for women with ruptured membranes between 34 and 37 weeks gestation to make recommendations for clinical practice. Further trials are necessary that should be of high quality, assess serious maternal and infant morbidity, assess the costs of care and provide information on neurodevelopment at childhood follow up.

#### **Current clinical practice in the management of PPRM in Australia and New Zealand**

In a recent survey of the Fellows and Members of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, we found there was no consensus on the management of PPRM [8]. In women who rupture their membranes at gestations greater than 34 weeks, 49% of obstetricians would manage these women expectantly with the patients remaining in hospital, while 51% of obstetricians would plan to deliver these women prior to term. This demonstrates the current diverse approach to the care of women with PPRM at greater than 34 weeks gestation, suggests that there is clinical equipoise and demonstrates the appropriateness of a clinical trial. Furthermore, 65% of the responding obstetricians would be willing to enrol women in a randomised

controlled trial of the management of PPRM at gestations greater than 34 weeks.

#### **Resource and cost implications of planned early delivery and expectant management of PPRM**

Expectant management may result in prolonged antenatal hospitalization, with antibiotic treatment and regular monitoring, and intensive care of the neonate in the event of sepsis. On the other hand, planned early delivery may necessitate intensive care of the neonate for problems associated with prematurity (eg respiratory distress). While some data are available for the US[18,19] and the UK[20], it is not known whether there are differences in the overall cost of care in the Australian setting. However, it is likely that the biggest drivers of health system costs will be the number of days admitted to hospital, particularly neonatal intensive care.

The trial is designed and sufficiently sized to detect a clinically significant difference in neonatal sepsis. We do not, however, expect differences in mortality or long-term morbidity between planned early delivery and expectant management. In the absence of differences in these final clinical outcomes, optimal treatment decisions will also require information about comparative resource use, and information about the preferences of women with PPRM. The secondary aim of the project is therefore to conduct a cost analysis of planned early delivery versus expectant management of PPRM and to establish the treatment preferences of women with PPRM.

Planned early delivery and expectant management represent very different experiences for the women involved. Currently, the relative importance to women of the attributes (health and non-health outcomes and process attributes) of the treatment alternatives is unknown. Discrete choice methodology takes into account the preferences of the mother and has been previously used to explore preferences in a number of relevant areas including intrapartum care[21], miscarriage[22], labour induction[23] and IVF[24]. Maternal preference is likely to assume more importance in the choice of management (of PPRM) if the long term outcomes of treatment are equivalent.

#### **Methods/Design**

##### **Aims**

The primary aim of the project is to conduct a randomised controlled trial to answer the clinical question: In women with preterm prelabour ruptured membranes (PPROM) between 34 weeks and 36<sup>6</sup> weeks gestation is planned early delivery compared with expectant management associated with less neonatal and maternal morbidity?

The secondary aim is to perform an economic analysis of the outcomes to establish the economic impact of planned early delivery compared with expectant management. The economic analysis will determine:

- the net impact of each intervention on hospital resources.
- which attributes of the treatment alternatives (such as time in hospital, risk of adverse outcomes, continuity of care etc) are important to women.
- the relative importance of these attributes.
- the extent to which women are prepared to make trade-offs between attributes.

### **Hypotheses**

The primary hypotheses are that early planned delivery of women with PPRM close to term is associated with:

1. less short-term neonatal and maternal morbidity compared with expectant management.
2. fewer economic costs compared with expectant management.
3. no difference in long term morbidity or mortality

### **Study design**

We will use a randomised controlled clinical trial to assess the impact of early planned birth versus expectant management.

### **Setting**

The study will be carried out in participating tertiary obstetric, metropolitan and rural hospitals with facilities to manage deliveries at or greater than 34 weeks.

### **Participants/Eligibility criteria**

Pregnant women between 34 and 36<sup>6</sup> weeks gestation with PPRM and a singleton pregnancy will be invited to participate in the trial. Women with ruptured membranes prior to 34 weeks gestation will become eligible at 34 weeks should their latency period extend to this gestation. Rupture of the membranes will be determined clinically and/or confirmed by a positive amniocentesis swab performed at the time of speculum examination. Gestational age will be determined by last menstrual period and/or by early ultrasound if there is a discrepancy of more than 7 days to that of the estimated date of confinement from the last menstrual period.

### **Exclusion criteria**

Women who are in established labour, have clinical evidence of chorioamnionitis or other indications for immediate delivery such as meconium staining of the liquor or an antepartum haemorrhage or any other contraindication to expectant management will be excluded from the study. The presence of Group B streptococcus on urine or genital tract culture will not be a specific indication for exclusion from the study.

### **Procedures, recruitment, randomisation and collection of baseline data**

Eligible women will be identified by a local research coordinator and staff. Eligible women will be given the trial information sheet, counselled and encouraged to discuss the trial with her family. Once women have consented to be involved in the trial, their entry details will be recorded on a trial entry form and they will be randomised via a central telephone randomisation service to one of two treatment groups, early planned birth or expectant management.

The randomisation schedule will be prepared by a researcher not involved with treatment allocation. Randomisation will be 1:1, in balanced variable blocks and stratified by centre.

All women will have baseline demographic, past obstetric and medical histories recorded. Maternal temperature will be recorded at a time as close to randomisation as possible. A vaginal swab will be collected from each participating woman and a fetal heart rate tracing obtained. Antibiotic administration is regarded as best practice in women presenting with PPRM and these should be administered in accordance with the policy of the participating centre [25]. At the collaborating centres, data collection will be the responsibility of the local research coordinator.

### **Intervention**

#### *Early planned delivery group*

Those women randomised to early planned birth will have delivery scheduled as close to randomisation as possible and preferably within 24 hours of randomisation. The mode of birth will be determined by usual obstetric indications. Antibiotics should be continued in the intrapartum period.

#### *Expectant management group*

In women randomised to expectant management birth will occur after spontaneous labour, at term or when the attending clinician feels that birth is indicated according to usual care.

Care of the all women will be otherwise managed by the obstetric team with care of the infant by the attending neonatologist.

#### **Follow up of women and infants in both treatment groups**

At birth arrangements should be made for the placenta to be examined histologically for chorioamnionitis and funisitis. The histological examiners will be blinded to treatment allocation. After birth, information will be obtained relating to birth and infant outcomes from the woman's and infant's case notes by the local research coordinator. A full blood count (FBC) will be collected on all babies with clinical signs consistent with bacterial, fungal or yeast infection and on all babies commenced on antibiotics. Four month questionnaires will be posted out to assess maternal wellbeing, satisfaction with care, breast feeding duration and early infant development.

#### **Outcome measures**

##### *Baseline data collection*

To assess the comparability of the study groups, baseline demographic and medical information will be collected from the medical record at the time of entry into the study.

##### *Primary outcome measure*

The primary outcome will be the incidence of neonatal sepsis. Sepsis will be classified as either definite or probable by an adjudication committee who will be unaware of the allocation group.

**Definite systemic neonatal infection** will be defined as the presence of clinical signs of infection and a positive culture of a known pathogen from blood or cerebrospinal fluid. For organisms of low virulence and/or high likelihood of skin contamination of the blood culture, such as coagulase negative *staphylococcus*, both a positive blood culture and an abnormal full blood count (FBC) are required.

*Clinical signs of infection* include respiratory distress, apnoea, lethargy, abnormal level of consciousness circulatory compromise (including hypotension, poor perfusion, need for inotropic support or volume expansion), poor feeding and/or temperature instability.

*An abnormal FBC count* includes an abnormal white cell count, low platelet count, abnormal neutrophil count, raised immature neutrophil count, raised immature to total neutrophil ratio and/or degenerative morphological changes to neutrophils (toxic granulation or vacuolization).

**Probable neonatal infection** will be defined as the presence of clinical signs of infection where the baby was

treated with antibiotics for 5 or more days together with one or more of: an abnormal FBC; an abnormal acute phase reactant (including C reactive protein [CRP] or positive Group B Streptococcal [GBS] antigen on bladder tap urine, blood or cerebrospinal fluid); growth of a known virulent pathogen (GBS, E. coli, Listeria) from surface swabs; or a histologic diagnosis of pneumonia in an early neonatal death.

##### *Secondary outcome measures*

##### *Secondary infant outcomes*

will include respiratory distress, perinatal mortality, duration of stay in a neonatal intensive or special care unit, duration of stay in hospital, birth weight, Apgar score at 5 minutes, any assisted ventilation, early infant development as measured by the women at four months (corrected age) using the ages for stages questionnaire [26].

##### *Secondary maternal outcomes*

will include antepartum, intrapartum and postpartum outcomes. Antepartum outcomes include chorioamnionitis, antepartum haemorrhage, thrombosis /thromboembolism, cord prolapse, treatment with antibiotics, and health service utilisation including laboratory tests, fetal well-being investigations and duration of hospitalisation. Intrapartum outcomes include induction of labour, failed induction of labour, caesarean section, assisted vaginal delivery, intrapartum bleeding or intrapartum fever and treatment with antibiotics. Placental swabs and histology will also be collected if available. Postpartum outcomes including postpartum infection treated with antibiotics, thrombosis/thromboembolism duration of hospitalisation, and initiation of breast feeding will be obtained from hospital records. Maternal satisfaction with care, maternal wellbeing, anxiety, and postnatal depression, and duration of breast feeding will be assessed at four months postpartum using self-report questionnaires. Maternal wellbeing will be assessed using the SF36 Health Survey Questionnaire [27]. SF-36 data will be examined as a single item measure of health and also by the Physical Component Summary and the Mental Component Summary. The scores for women randomised to immediately delivery and expectant care will be compared at baseline and at 4 months postpartum. Anxiety will be measured by the state component of the short Spielberger anxiety scale which has been extensively used and validated [28]. Postnatal depression will be assessed using the 10-item Edinburgh Postnatal Depression Scale, a self-report measure of depression developed for use in the postpartum period [29].

##### **Economic evaluation**

The economic questions being addressed in this study are "given the equivalence in long term morbidity and mortality between immediate delivery and expectant manage-

ment for women with PPRM, what is the least cost alternative from the viewpoint of a health care funder"? and "what are the (utility-based) preferences of women with PPRM for their clinical management"? A cost analysis will be conducted in accordance with the methods outlined by Drummond et al 1997 [30]. This will involve an initial analysis on what resource utilization data can be collected on the patient case report forms, from patient medical records and from routine data collection. It is likely that the biggest drivers of cost will be the number of days admitted to hospital, particularly neonatal intensive care. The methodology for hospital cost will include micro-costing (where differences in resource utilization between patient groups are likely to be important to the final results) and components of case mix cost weights (where utilization is more likely to be similar within patient groups).

Discrete choice methods will be used to establish maternal preferences, using established methods [31]. We will generate a questionnaire based on pair-wise choices similar to the example shown in Table 2. The questionnaire will be administered in face-to-face interviews with a sample of women enrolled in the PPRM trial. A deterministic sensitivity analysis will be employed where individual parameters are varied one at a time. A random effects probit regression analysis will be used to analyse patient responses to the discrete choice survey, identifying which attributes are important, and the trade-offs between attributes that women are prepared to make.

**Statistical issues**

*Sample size*

The trial is designed to demonstrate a 50% reduction in proven or probable neonatal sepsis from 5% in those women managed expectantly to 2.5% in those women managed with immediate delivery. This requires a total sample size of 1812 women with 80% power and a significance level of  $p = 0.05$ . The estimated neonatal sepsis rate of 5% is based on discussions with neonatologists and is conservative compared with the systematic review (6.2% in control arms, where a 50% reduction would require 1448 women). For women who agree to participate we expect almost complete follow-up on the primary out-

comes as these will be obtained from the medical records. This sample size will also have adequate power to demonstrate an increase in the need for ventilatory support from 4% in the expectant arm to 7% in the immediate delivery arm.

*Data analysis*

Analyses will be by intention to treat, including withdrawals and losses to follow-up. Study groups will be compared in terms of baseline characteristics. As this is a randomised trial, we would anticipate minimal differences in baseline characteristics. If however, important differences are found, these potential confounders will be adjusted for in the analysis of outcomes. For the primary outcome, the relative risk (and 95% confidence interval) of neonatal sepsis in the early planned delivery group compared with the expectant group will be calculated. If adjustment for confounding is necessary logistic regression will be used. The secondary outcomes will be compared using chi-square tests of significance for categorical data and t-tests for continuous data. If adjustment for confounding is necessary logistic regression and multiple linear regression will be used respectively.

*Interim analysis*

An interim analysis by an independent data monitoring committee with established terms of reference will be conducted when 50% of women have been recruited. If there is proof beyond reasonable doubt that an arm of the study is either clearly indicated or contra-indicated, the trial will be stopped prematurely. A difference of at least three standard deviations in interim analysis of a major end-point is needed to justify stopping the trial. All perinatal deaths will be reviewed by a multidisciplinary adverse events committee blinded to treatment allocation.

**Ethical considerations**

To date the study has been approved by the following ethics committees: Northern Sydney and Central Coast Area Health Service for the Royal North Shore and Hornsby Kuringgai Hospitals (Ref. No. 0306-126M), University of Adelaide at the Women's & Children's Hospital (Ref. No. REC 1531/11/2006), Ramsay Health for North Shore Private Hospital (Ref. No. 0306-126M), University of Sydney

**Table 2: Example of a discrete choice question with pair-wise choices**

	Early planned birth	Wait for labour
Time in hospital prior to giving birth	No time	2 weeks
Likelihood of spontaneous vaginal birth	X%	Y%
Time mother spends in hospital after giving birth	1 week	3 weeks
Time baby spends in neonatal intensive care	2 weeks	No time
Which would you choose? (Please circle one only)	Early planned birth or Wait for labour	

Human Research Ethics Committee (Ref. No. 7988), Sydney South West Area Health Service Ethics Review Committee for the Royal Prince Alfred Hospital (Protocol No. X04-0167), Western Sydney Area Health Service for Westmead Hospital (Ref. No. HREC2005/2/4.23(2028)) and Nepean Hospital (Ref. No. HREC2005/2/4.23(2028)), Townsville Health Service District (Ref. No. 43/05).

### Confidentiality and data security

Participants in the trial will be identified by a study number only, with a master code sheet linking names with numbers being held securely and separately from the study data. To ensure that all information is secure, data records will be kept in a secure location at the Royal North Shore Hospital in Sydney and accessible only to research staff. As soon as all follow-up is completed the data records will be de-identified. De-identified data will be used for the statistical analysis and all publications will include only aggregated data.

The electronic version of the data will be maintained on a computer protected by password. All hard copy patient identifiable data and electronic backup files will be kept in locked cabinets, which are held in a locked room accessed only by security code and limited staff. Data files will be stored for 7 (seven) years after completion of the project as recommended by the National Health and Medical Research Council (NHMRC). Disposal of identifiable information will be done through the use of designated bags and/or a shredding machine.

## Discussion

### Outcomes and significance

At gestations remote from term, expectant management is appropriate to allow fetal maturation. When PPRM complicates pregnancies closer to term the risks of prematurity are lower and the risk to the infant of sepsis becomes of greater significance. This trial will provide evidence on the optimal care for women with PPRM close to term (34–37 weeks gestation). If it can be demonstrated that early planned birth in this clinical situation is associated with less maternal and neonatal morbidity this will change current practice. The findings of the study will also have significant resource implications as PPRM close to term is a frequent indication for antenatal admission. The trial allows for a detailed assessment of the costs associated with the care of the neonate from the two different care strategies. Given the null hypothesis of no differences between planned early birth and expectant management in mortality or long-term morbidity, information about preferences will allow women and their clinicians to make optimal treatment choices. Information about both preferences and costs will assist policymakers in deciding if, and how, treatment options are presented to women with PPRM. The results of the economic eval-

uation are thus expected to improve both clinical decision-making and the management of hospital resources. Therefore, analysis of both the clinical and economic sequelae of immediate birth as opposed to expectant management will enable informed decisions and guidelines to be formulated.

### Abbreviations

PPROM – preterm prelabour rupture of the membranes

FBC – full blood count

CRP – C reactive protein

GBS – Group B Streptococcus

### Competing interests

The author(s) declare that they have no competing interests.

### Authors' contributions

JM, SB, CR and CC were involved in the conception and design of the study. JM, SB, CR, CC, DHS, GS were all responsible for the drafting of the protocol and were involved in the development and implementation of the study. All authors have read and given final approval of the final manuscript.

### Acknowledgements

This study is funded by an Australian National Health and Medical Research Council project grant (358387). Christine Roberts is funded by an Australian National Health and Medical Research Council Public Health Practitioner Fellowship. Our especial thanks to Kate Levett for coordinating the PPRM trial.

### References

- Grant J, Keirse MJNC: **Prelabour rupture of the membranes at term.** In *Effective Care in Pregnancy and Childbirth* Edited by: Chalmers I, Enkin M and Keirse MJNC. Oxford, Oxford University Press; 1989:1112-1117.
- Hannah ME, Ohlsson A, Farine D, Hewson SA, Hodnett ED, Myhr TL, Wang EE, Weston JA, Willan AR: **Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group.** *N Engl J Med* 1996, **334**:1005-1010.
- Arias F, Tomich P: **Etiology and outcome of low birth weight and preterm infants.** *Obstet Gynecol* 1982, **60**:277-281.
- Mercer BM: **Preterm premature rupture of the membranes.** *Obstet Gynecol* 2003, **101**:178-193.
- Gonen R, Hannah ME, Milligan JE: **Does prolonged preterm premature rupture of the membranes predispose to abruptio placentae?** *Obstet Gynecol* 1989, **74**:347-350.
- Major CA, de Veciana M, Lewis DF, Morgan MA: **Preterm premature rupture of membranes and abruptio placentae: is there an association between these pregnancy complications?** *Am J Obstet Gynecol* 1995, **172**:672-676.
- Bendon RW, Faye-Petersen O, Pavlova Z, Qureshi F, Mercer B, Miodovnik M, Das AF, Meis PJ, Moawad AH, Iams JD, McNellis D: **Fetal membrane histology in preterm premature rupture of membranes: comparison to controls, and between antibiotic and placebo treatment.** *Pediatr Dev Pathol* 1999, **2**:552-558.
- Buchanan S, Crowther C, Morris J: **Preterm prelabour rupture of the membranes: a survey of current practice.** *Aust N Z J Obstet Gynaecol* 2004, **44**:400-403.

9. Robertson PA, Sniderman SH, Laros RKJ, Cowan R, Heilbron D, Goldenberg RL, Iams JD, Creasy RK: **Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986.** *Am J Obstet Gynecol* 1992, **166**:1629-1645.
10. Goldenberg RL, Nelson KG, Davis RO, Koski J: **Delay in delivery: influence of gestational age and the duration of delay on perinatal outcome.** *Obstet Gynecol* 1984, **64**:480-484.
11. Kramer MS, Demissie K, Yang H, Platt RW, Sauve R, Liston R: **The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System.** *Jama* 2000, **284**:843-849.
12. Wu YW, Colford JM: **Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis.** *Jama* 2000, **284**:1417-1424.
13. Gaudet LM, Smith GN: **Cerebral palsy and chorioamnionitis: the inflammatory cytokine link.** *Obstet Gynecol Surv* 2001, **56**:433-436.
14. Buchanan SL, Crowther CA, Morris J: **Planned early birth versus expectant management for women with preterm prelabour rupture of membranes at 34 to 37 weeks' gestation for improving pregnancy outcome.** (Protocol) *The Cochrane Database of Systematic Reviews* 2004, Issue 2. Art. No.: **CD004735**. DOI: **10.1002/14651858.CD004735**.
15. Spinnato JA, Shaver DC, Bray EM, Lipshitz J: **Preterm premature rupture of the membranes with fetal pulmonary maturity present: a prospective study.** *Obstet Gynecol* 1987, **69**:196-201.
16. Mercer BM, Crocker LG, Boe NM, Sibai BM: **Induction versus expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial.** *Am J Obstet Gynecol* 1993, **169**:775-782.
17. Naef RW, Allbert JR, Ross EL, Weber BM, Martin RV, Morrison JC: **Premature rupture of membranes at 34 to 37 weeks' gestation: aggressive versus conservative management.** *Am J Obstet Gynecol* 1998, **178**:126-130.
18. Magriples U, Crichton R, Ehrenkranz R, Copel JA: **Delivery at 34 weeks is more costly than at 35 weeks in pregnancies with premature rupture of membranes.** *J Matern Fetal Neonatal Med* 2003, **14**:22-25.
19. Grable IA: **Cost-effectiveness of induction after preterm premature rupture of the membranes.** *Am J Obstet Gynecol* 2002, **187**:1153-1158.
20. Petrou S, Davidson LL: **Economic issues in the follow-up of neonates.** *Semin Neonatol* 2000, **5**:159-169.
21. Hundley V, Ryan M, Graham W: **Assessing women's preferences for intrapartum care.** *Birth* 2001, **28**:254-263.
22. Ryan M, Hughes J: **Using conjoint analysis to assess women's preferences for miscarriage management.** *Health Econ* 1997, **6**:261-273.
23. Taylor S, Armour C: **Consumer preference for dinoprostone vaginal gel using stated preference discrete choice modeling.** *Pharmacoeconomics* 2003, **21**:721-735.
24. Ryan M: **Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in vitro fertilisation.** *Soc Sci Med* 1999, **48**:535-546.
25. Kenyon S, Boulvain M, Neilson J: **Antibiotics for preterm rupture of membranes.** *The Cochrane Database of Systematic Reviews* 2003, Issue 2. Art. No.: **CD001058**. DOI: **10.1002/14651858.CD001058**.
26. Bricker D, Squires J, Mounts L: **Ages and stages questionnaire: 4 month: A parent completed child monitoring system.** USA, Paul H Brookes Publishing Co; 1995.
27. Ware JE, Sherbourne CD: **The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.** *Med Care* 1992, **30**:473-483.
28. Marteau TM, Bekker H: **The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI).** *Br J Clin Psychol* 1992, **31**:301-306.
29. Cox JL, Holden JM, Sagovsky R: **Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale.** *Br J Psychiatry* 1987, **150**:782-786.
30. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW: **Methods for the Economic Evaluation of Health Care Programmes.** 2nd edition. Oxford, Oxford University Press; 1997.
31. Louviere JJ, Hensher DA, Swait JD: **Stated Choice Methods.** Cambridge, Cambridge University Press; 2000.

## Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2393/6/9/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

